IMB Dx, Inc. (KOSDAQ:461030)

Market Cap	142.28B
Revenue	n/a
Net Income	n/a
Shares Out	14.02M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,706
Average Volume	220,481
Open	10,390
Previous Close	10,390
Day's Range	9,960 - 10,520
52-Week Range	8,430 - 40,550
Beta	n/a
RSI	44.72
Earnings Date	n/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 461030